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Abstract 
Several diseases would benefit from prolonged drug release provided by systems retained in the 
stomach for extended time periods. Expandable gastroretentive devices are administered in a 
collapsed configuration enabling swallowing and regain in situ their native shape having larger spatial 
encumbrance, thus hindering voidance through the wide open pylorus. An expandable system for 
gastric retention was here proposed relying on the shape memory behavior of pharmaceutical-grade 
poly(vinyl alcohol). Different original configurations to be recovered upon exposure to aqueous fluids 
at 37 °C, potentially enabling gastric retention, were conceived. Prototypes containing allopurinol 
were directly manufactured by fused deposition modeling or shaped by purposely-designed templates 
from hot melt extruded rods immediately after production. Various temporary shapes, in principle 
suitable for administration, were programmed by manual deformation of samples by means of 
specific templates, under defined temperature conditions. In 0.1N hydrochloric solution at 37 °C, the 
prototypes recovered their original shape, reaching the desired spatial encumbrance within few 
minutes. Release from the samples, although of relatively short duration, was independent of the 
original shape and processing undergone, and was noticeably slowed down by application of Eudragit 
RS/RL-based coatings. 
 
 
 
Keywords: poly(vinyl alcohol); shape memory polymer; hot melt extrusion; fused deposition 
modeling; 4D printing; gastroretentive drug delivery system. 
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1. Introduction 
Recently, the use of the water-induced shape memory response of swellable soluble polymers was 
demonstrated to be a viable strategy for the development of an indwelling delivery system for 
intravesical administration of drugs (Melocchi et al., 2019). The system, based on poly(vinyl alcohol) 
(PVA) of pharmaceutical grade, was fabricated via hot melt extrusion (HME) and 3D printing by 
fused deposition modeling (FDM) in a permanent bulky shape enabling retention within the bladder. 
Its ability to i) be fixed to a temporary shape suitable for administration, ii) recover the stress-free 
permanent shape following interaction with simulated urine at body temperature and iii) 
dissolve/erode while releasing a drug tracer was demonstrated. Moreover, it was the first 4D printing 
attempt of a drug delivery system (DDS) using pharmaceutical-grade polymers. A similar approach 
could be advantageously applied to the development of drug delivery systems to be retained in another 
hollow organ, such as the stomach, wherein sustained concentrations of drugs are needed in a number 
of disease conditions. 
Gastric retention has long been pursued to enhance the bioavailability of drugs having either an 
absorption window in the upper gastrointestinal tract (e.g. metformin hydrochloride, baclofen) or 
lower solubility in the intestinal environment (e.g. captopril, metronidazole, ranitidine 
hydrochloride), and would also be desirable for the local treatment of gastric or duodenal ulcers, 
esophagitis and eradication of Helicobacter pylori (Altreuter et al., 2018; Bardonnet et al., 2006; 
Gupta et al., 2018; Kumar and Kaushik 2018; Lopes et al., 2016) The use of prolonged-release 
gastroretentive drug delivery systems (GRDDSs) would also increase patient compliance by reducing 
the dosing frequency. Moreover, it would improve the therapy efficacy by limiting fluctuations in the 
drug concentration. Therefore, it would be highly advantageous in poor-adherence populations (e.g. 
children, elderly people and patients with cognitive/mental disorders) and in the therapy of chronic 
diseases (e.g. diabetes, HIV) that currently require drug administration via injection or other invasive 
procedures. In the latter case, major benefits would be obtained by prolonging drug release over 
days/weeks/months. However, gastric retention represents a quite challenging goal due to anatomical, 
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mechanical, hydrodynamic and chemical issues involved, such as peristaltic contractions and 
housekeeper waves, variable fluid volume, propulsive and retropulsive jets of gastric fluid, enzymatic 
processes, acidic pH. Inter-individual variables, e.g. gender, age, diet, alcohol consumption, physical 
activity, comorbidities and medications, may also play a critical role. 
In order to enable gastric retention, a variety of approaches have been proposed in the scientific 
literature over the years, basically relying on i) density modifications, leading to devices undergoing 
high-density sedimentation or low-density floatation, ii) adhesion to the gastric mucosa, iii) magnetic 
localization and/or iv) size increase preventing passage through the pylorus (Altreuter et al., 2018). 
Size-increasing GRDDSs, also known as expandable gastroretentive systems, were initially 
developed for veterinary application and currently represent one of the most promising strategies 
(Kumar and Kaushik 2018; Lopes et al., 2016; Chen et al., 2000; Klausner et al., 2003a, 2003b; 
Omidian et al., 2005; Verma et al., 2014). Few of them have already received FDA approval or are 
in phase III clinical trials (e.g. Depomed’s Acuform® technology, IntecPharma’s Accordion Pill™) 
(Altreuter et al., 2018; Klausner et al., 2003b). For safety and efficacy purposes, these systems have 
to fulfill a number of requirements including i) convenient and well-tolerated administration mode, 
ii) prompt achievement of the bulky configuration only upon entry into the gastric environment, iii) 
retention for a programmed period of time without damaging the stomach walls or interfering with 
the relevant motility, iv) mechanical resistance to counteract muscle contraction, v) controlled release 
of the drug conveyed irrespective of diverse physiological conditions (e.g. pH fluctuations, presence 
of food and liquid content), and vi) elimination following reduction in size. In particular, the latter 
process should take place in such a way as not interfere with physiological stomach emptying and be 
completed before the administration of a subsequent dose, thus circumventing the risk of 
accumulation of multiple devices. 
Expandable GRDDSs can be distinguished based on the ability to either take on a bulky configuration 
in the stomach by swelling, or go back to the bulky shape in which they were fabricated. In the latter 
case, the system is forced after production to a collapsed configuration which enables easy 
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swallowing, typically within a carrier dosage form (e.g. a capsule), for instance by folding. Once in 
the stomach, the system regains its native configuration with larger spatial encumbrance, preventing 
passage through the wide open pylorus that has diameter ranging between 5.6 mm and 22.1 mm, more 
commonly reported to be of 11 - 13 mm (Altreuter et al., 2018). 
Pioneering research in the field of expandable GRDDSs was recently performed at Massachusetts 
Institute of Technology (MIT), leading to innovative systems based on either swelling or unfolding 
(Bellinger et al., 2016; Kirtane et al., 2018; Liu J. et al., 2017; Liu X. et al., 2019). In both cases, great 
attention was focused on the mechanism of voidance of the devices. Particularly, gastric emptying of 
the exhausted system was ensured by a decrease in its size, either brought about by exposure to 
specific substances administered orally when appropriate, or associated with weakening/breaking of 
purposely designed portions due to diminished resistance to gastric contractions. 
Based on these premises, the aim of the present work was to evaluate the feasibility of an expandable 
GRDDS able to self-modify its configuration upon external stimuli relying on the water-induced 
shape memory response of pharmaceutical-grade poly(vinyl alcohol) (PVA). The proposed system 
would thus spontaneously shift from a temporary collapsed configuration, imposed to allow 
administration, to a bulky original one enabling retention. Unlike previously described expandable 
GRDDSs based on unfolding, such a shifting would be programmed to occur in a time-dependent 
mode upon interaction with gastric fluid at body temperature rather than upon removal of a 
mechanical constraint (e.g. dissolution of the capsule). Therefore, the proposed device would result 
in a shape-memory expandable GRDDS (SMX GRDDS). Taking advantage of the experience gained 
in the use of FDM and HME, these techniques were selected for manufacturing of the device in view 
of the versatility in geometry they are well known to provide, which is of utmost importance due to 
the critical role played by shape for gastric retention (Beck et al., 2017; Genina et al., 2017; Goyanes 
et al., 2016; Kollamaram et al., 2018; Loreti et al., 2014; Maroni et al., 2017; Matijašić et al., 2019; 
Melocchi et al., 2015a, 2015b,2018). Dealing with FDM, because recovery of the original shape of 
the 3D printed device is expected to take place over a set period of time, time itself would be 
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considered as the fourth dimension, thus resulting in 4D printing (Gao et al., 2016; Lee et al., 2017; 
Zarek et al., 2015, 2017). This concept refers to production, via different 3D printing techniques, of 
objects based on smart materials such as shape-memory polymers, intended for self-transformation 
when exposed to proper external stimuli other than mechanical ones (Ding et al., 2017; Huang et al., 
2010; Maniruzzamann, 2018). Interestingly, the approach to gastric retention here pursued has not 
been used before or reported in the scientific literature, and would also benefit from regulatory 
acceptability on account of the safety profile of the polymer employed (Melocchi et al., 2018, 2019). 
Thanks to the solubility of PVA, this system could also be subject to elimination from the stomach 
because of modification in its steric hindrance and mechanical properties over time, by gradually 
softening, dissolving and/or eroding when hydrated. 
The feasibility of the SMX GRDDS was evaluated by i) designing original shapes in principle 
enabling gastric retention and setting up appropriate process conditions for manufacturing, ii) 
identifying temporary shapes compatible with oral administration into capsules and methods for their 
programming and iii) characterizing the obtained prototypes for water-induced shape recovery and 
release performance. At first, fabrication of systems by FDM was attempted. Subsequently, HME 
was used, and a systematic work was performed with extruded samples, including study of different 
shapes, quantitative evaluation of shape recovery and preliminary coating experiments. 
 
2. Materials and Methods 
2.1 Materials 
PVA of different molecular weights (PVA05 and PVA18; Gohsenol™ EG 05P and Gohsenol™ EG 
18P, Nippon Gohsei, J); glycerol (GLY; Pharmagel, I); methacrylic acid copolymer Eudragit® RL100 
and Eudragit® RS100 (Evonik, D); triethyl citrate (Sigma Aldrich, D) allopurinol (ALP; 
FarmaQuimica sur S.L., ES; boiling point 250.36 °C, melting point > 300 °C) 
(https://www.drugbank.ca/drugs/DB00437); carbonium nylon filament (ø = 1.75 mm, 
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TreeDFilaments, I); hard-gelatin Coni-snap® capsule size 00el (capacity 1.02 mL, body external 
diameter 8.18 ± 0.06 mm, overall closed length 25.3 mm ± 0.03) and DB caps® size AA (capacity 
0.80 mL, internal diameter 9.39 ± 0.06 mm, overall closed length 17.5 ± 0.03 mm) (Capsugel, I). 
 
2.2. Methods 
2.2.1 Preparation of PVA-based materials 
Plasticized polymeric formulations containing 15% by weight of GLY calculated on the dry polymer 
were prepared starting from PVA05 and PVA18 (PVA05GLY and PVA18GLY). PVA powder, 
previously kept in an oven at 40 °C for 24 h, was placed in a mortar and GLY was added dropwise 
under continuous mixing. The resulting mixture was dried at 40 °C for 8 h and possible aggregates 
were then ground by a blade mill. The < 250 µm powder fraction was collected and used. Drug-
containing materials were prepared immediately before processing by mixing in a mortar ALP 
powder, previously oven-dried at 40 °C for 24 h, with PVA05GLY or PVA18GLY in a 1:9 weight 
ratio (PVA05GLY-ALP and PVA18GLY-ALP, respectively). 
 
2.2.2 Fabrication of SMX GRDDS prototypes 
SMX GRDDS prototypes entailed an original shape resulting from fabrication and a temporary shape 
attained by programming (Figure 1). Preparation steps were different according to whether FDM or 
HME was used. 
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Figure 1: preparation steps of SMX GRDDS prototypes by (a) HME and (b) FDM. 
 
2.2.2.1 Hot melt extrusion 
Extrusion was performed by a twin-screw extruder (Haake™ MiniLab II, Thermo Scientific, US-WI) 
equipped with counter-rotating screws and different dies under the conditions reported in Table 1. 
 
Table 1: HME process conditions and maximum torque values recorded. 
Material 
HME 
T (°C) Screw speed (rpm) Torque (N·cm) 
PVA05GLY 170 20 100 
PVA05GLY-ALP 175 20 120 
PVA18GLY 200 20 190 
PVA18GLY-ALP 200 20 210 
 
HME was both employed to fabricate filaments for FDM and rods to be shaped into SMX GRDDS 
prototypes in their original shape. 
Filaments were fabricated from PVA05GLY-based materials by extrusion through a custom-made 
aluminum circular die (ø = 1.80 mm), as previously described (Melocchi et al., 2016, 2019). In order 
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to counteract possible swelling phenomena and enhance the yield for filament compliant with the pre-
established diameter specifications (1.75 ± 0.05 mm), the material coming out of the extruder was 
manually pulled to pass through a caliper connected with the equipment and set at 1.80 mm. After 
production and cooling, filament diameter was verified every 5 cm in length, and portions out of 
specifications were discarded. 
Rods were fabricated from PVA18GLY-based materials by extrusion through a custom-made 
aluminum circular die (ø = 1.00 mm). While still hot, the rod was wrapped around purposely-
developed templates, as described in the Results and Discussion section, and removed after 2 min of 
cooling under pressurized air. Samples having different original shapes, i.e. conical and cylindrical 
helices, S-shaped and atom-shaped samples, were thereby obtained. The resulting prototypes were 
packed in heat-sealed alufoil moisture barrier bags before being employed. 
Samples of cylindrical helix shape were manually coated up to 60% weight gain with a 14% w/w 
ethanolic solution of Eudragit RS/Eudragit RL (1/1 w/w) plasticized with 15% w/w of triethyl 
citrate on the dry polymers. Coating was performed at ambient conditions inside an isolated room 
equipped with an air intake system, a spraying system with a 0.8 mm nozzle (pump speed 10 rpm, 
atomizer 0.75 atm, pattern 1 atm), and a rotating gear (2.3 rpm) enabling planetary movements. 
Coated samples were cured in a ventilated oven at 40 °C for 2 h. 
 
2.2.2.2 3D printing 
FDM was performed by a Kloner3D 240® Twin (Kloner3D, I) printer equipped with 0.5 mm nozzle. 
Computer-aided design (CAD) files were purposely developed as described in the Results and 
Discussion section using Autodesk® Autocad® 2016 software version 14.0 (Autodesk Inc., US-CA) 
and Netfab (I), specifically employed to increase the mesh number of virtual models. Designs were 
saved in .stl format and imported to the printer software (Simplify 3D, I). FDM 3D printing was both 
employed to directly fabricate prototypes of SMX GRDDSs in their original shape and templates. 
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Such templates were in turn employed for manual post-processing of extruded rods, to achieve the 
desired original shape of prototypes, and for programming of their temporary shape. 
Prototypes of SMX GRDDSs in their original shape were printed using 25 cm-long portions of the 
in-house prepared PVA05GLY-ALP filament (printing temperature = 200 °C, infill = 100%, layer 
height = 0.10 mm, printing speed = 23 mm/s, separation gap for raft and supports = 0.5 mm). 
Templates were printed from commercial carbonium nylon filament used as received (printing 
temperature = 230 °C, infill = 100%, layer height = 0.10 mm, printing speed = 50 mm/s). 
 
2.2.2.3 Programming of the temporary shape 
Programming of the temporary shape was performed by heating samples up to the deformation 
temperature ≈ Tg + 35 °C (where Tg is the material glass transition temperature measured by DSC), 
and manually deforming them with or without using templates, as described in the Results and 
Discussion section. The temporary shape was then fixed by cooling the deformed samples at -20 °C 
(well below Tg). The deformed specimens were maintained under this temperature for at least 1 h 
before testing. 
 
2.2.3 Evaluation of SMX GRDDS prototypes 
2.2.3.1 Shape recovery 
Recovery of the original shape was studied upon immersion of the deformed samples into a 
crystallization vessel, filled with 250 mL of unstirred HCl 0.1 N and kept at 37 ± 0.5 °C by means of 
a thermoregulated bath. When the samples in their temporary shape were inserted into a capsule, the 
latter was glued to a microscope slide placed into the crystallization vessel to avoid floating. The 
recovery process was monitored using digital cameras positioned above (distance 13 cm) and in front 
of (distance 10 cm) the specimen (GoPro Hero Session, US-CA; n = 3). The photographs acquired 
were processed using a specific software (ImageJ, US-MD). For each shape, recovery indices were 
calculated and recovery index (RI) versus time curves were built. RI were calculated as follows: 
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- for samples having original cylindrical helix shape (Figure 2a), which undergo supercoiling and 
extension in the programming of the temporary shape 
𝑅𝐼∅(%) =
∅𝑡−∅0
∅𝑖−∅0
× 100       (Eq. 1) 
where RIØ is the diameter recovery index, being Øi the diameter measured in the original 
configuration, Ø0 the diameter measured in the temporary shape and Øt the diameter measured during 
shape recovery; 
𝑅𝐼∅ ℎ ⁄ (%) =
(∅/ℎ)𝑡−(∅/ℎ)0
(∅/ℎ)𝑖−(∅/ℎ)0
× 100      (Eq. 2) 
where RIØ/h is the diameter-to-height ratio recovery index, being (∅/ℎ)𝑖 the diameter-to-height ratio 
measured in the original configuration, (∅/ℎ)0 the diameter-to-height ratio measured in the 
temporary shape and (∅/ℎ)𝑡 the diameter-to-height ratio measured during shape recovery; 
- for samples having original conical helix shape (Figure 2b), which undergo supercoiling and 
extension in the programming of the temporary shape 
𝑅𝐼∅(%) =
∅𝑡−∅0
∅𝑖−∅0
× 100       (Eq. 3) 
where RIØ is the base diameter recovery index being Øi the base diameter measured in the original 
configuration, Ø0 the base diameter measured in the temporary shape and Øt the base diameter 
measured during shape recovery; 
𝑅𝐼∅ ℎ ⁄ (%) =
(∅/ℎ)𝑡−(∅/ℎ)0
(∅/ℎ)𝑖−(∅/ℎ)0
× 100      (Eq. 4) 
where RIØ/h is the base diameter-to-height ratio recovery index, being (∅/ℎ)𝑖 the base diameter-to-
height ratio measured in the original configuration, (∅/ℎ)0 the base diameter-to-height ratio 
measured in the temporary shape and (∅/ℎ)𝑡 the base diameter-to-height ratio measured during shape 
recovery; 
- for samples having original S shape (Figure 2c), which undergo a complex deformation into a paper 
clip shape during the programming of the temporary shape 
𝑅𝐼𝛼𝑥𝑦(%) =
𝛼𝑥𝑦𝑡−𝛼𝑥𝑦0
𝛼𝑥𝑦𝑖−𝛼𝑥𝑦0
× 100      (Eq. 5) 
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where 𝑅𝐼𝛼𝑥𝑦 is the αxy recovery index, being 𝛼𝑥𝑦𝑖 the angle measured in the original shape, 𝛼𝑥𝑦0   the 
angle measured in the temporary shape and 𝛼𝑥𝑦𝑡 the angle measured during shape recovery; 
𝑅𝐼𝛼𝑦𝑧(%) =
𝛼𝑦𝑧𝑡−𝛼𝑦𝑧0
𝛼𝑦𝑧𝑖−𝛼𝑦𝑧0
× 100      (Eq. 6) 
where 𝑅𝐼𝛼𝑦𝑧 is the αyz recovery index, being 𝛼𝑧𝑦𝑖 the angle measured in the original shape, 𝛼𝑦𝑧0   the 
angle measured in the temporary shape and 𝛼𝑧𝑦𝑡 the angle measured during shape recovery; 
𝑅𝐼𝛼𝑥𝑧(%) =
𝛼𝑥𝑧𝑡−𝛼𝑥𝑧0
𝛼𝑥𝑧𝑖−𝛼𝑥𝑧0
× 100       (Eq. 7) 
where 𝑅𝐼𝛼𝑥𝑧 is the αxz recovery index, being 𝛼𝑥𝑧𝑖 the angle measured in the original shape, 𝛼𝑥𝑧0   the 
angle measured in the temporary shape and 𝛼𝑥𝑧𝑡 the angle measured during shape recovery. 
Since the samples can lie on two different planes in the crystallization vessel once they are no longer 
inside the capsule, only two angles can be measured at a time during the recovery of the original S 
shape. Therefore, the experiments for S-shaped samples were replicated twice. In Figure 2c an 
example is shown where αxy and αxz were measured on the same specimen by the two cameras, and 
αyz was evaluated on a different sample. 
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Figure 2: (left) virtual models of (a) cylindrical helix-, (b) conical helix- and (c) S-shaped samples, 
and (right) photographs of relevant specimens during shape recovery; parameters (i.e. diameter, 
height and angles) used to calculate RI are indicated. 
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2.2.3.2 Release performance 
ALP-containing samples, either immediately after fabrication or following deformation into their 
temporary shape and insertion into a capsule, were tested for release using a USP38 dissolution 
apparatus 2 (50 rpm, 37 ± 0.5 °C, 900 mL HCl 0.1 N; Distek, CH; n = 6). Fluid samples were 
withdrawn at specific time points and assayed spectrophotometrically (λ = 251 nm). During the 
release test, photographs of samples were acquired every 5 s (GoPro Hero Session, US-CA). 
 
2.2.4 Differential scanning calorimetry (DSC) 
DSC analyses were performed by a DSC Q100 TA Instruments equipment (US-DE; n = 1), using 
nitrogen as a purge gas (70 mL/min). Indium was used as a calibration standard. Samples of about 10 
mg were heated in aluminum pans from -50 °C to 240 °C, maintained at this temperature for 1 min, 
cooled down to -50 °C and reheated up to 240 °C. Both the heating and cooling steps were run at 10 
°C/min. 
 
3. Results and Discussion 
Taking advantage of the experience previously gained in the development of indwelling PVA-based 
devices for intravesical administration of drugs, the main challenges to be faced were related to the 
peculiar characteristics of the new site for DDS retention. 
 
3.1 Drug tracer selection 
ALP, a xanthine oxidase inhibitor used as the first-line therapy for gout and hyperuricemia, was 
chosen as a model molecule in view of its greater absorption from the stomach, being in its non-
ionized form in the acidic medium (pKa 9.4), and from the duodenum as well as the upper jejunum 
(Jaeger et al., 1982; Rouge et al., 1996; Sharma et al., 2015). Indeed, this drug has already been 
proposed as a candidate for being administered via a GRDDS combining floating and mucoadhesion 
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strategies (Sharma et al., 2015). Moreover, its high melting point would make it in principle suitable 
for processing under the temperature conditions required by the employed manufacturing techniques. 
PVA-based formulations containing ALP, and GLY as the plasticizer, were subjected to a DSC cycle 
between -50 °C and 240 °C in order to assess the material Tg. Indeed, the temporary shape of a PVA-
based SMX GRDDS has to be programmed by heating samples above Tg, and maintained by keeping 
them below Tg. Moreover, the recovery of the original shape would occur when the systems are 
exposed at a temperature above Tg, i.e. the body temperature. In Figure 3 DSC thermograms acquired 
are reported. 
 
Figure 3: DSC thermograms (a) PVA05- and (b) PVA18-based materials. Thermograms relevant to 
ALP as such are also reported. 
 
The plasticization effect of GLY on PVA, indicated by a decrease in Tg, was confirmed (Melocchi et 
al., 2019; Mohsin et al., 2011). On the contrary, the presence of ALP was demonstrated not to affect 
the Tg of PVA05GLY and PVA18GLY. 
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3.2 Design concept 
The original and the temporary shape of the SMX GRDDS under development should be compliant 
with the route of administration and the characteristics of the retentive organ. Accordingly, the 
original shape given on fabrication was conceived so as to provide the system with a spatial 
encumbrance that would prevent stomach emptying, i.e. at least 2 dimensions greater than 13 mm. 
Moreover, it would have to be endowed with large void volumes not to prevent passage of gastric 
fluids through the pyloric sphincter, should the device be positioned in its close proximity during 
residence in the stomach. On the other hand, the temporary shape to be imposed by subsequent 
deformation should be such as to allow conveyance of the device in a carrier system (e.g. a gelatin 
capsule) and easy swallowing. The shift from the latter to the former configuration should 
spontaneously take place after dissolution/breakup of the capsule in the gastric fluid, while 
elimination of the expanded system from the stomach would be ensured by the progressive dissolution 
of PVA. 
 
3.3 4D printing of prototypes 
FDM was first used for the manufacturing of SMX GRDDS prototypes, and a trial-and-error approach 
was adopted. This consisted in introducing progressing changes into the virtual model (e.g. diameter, 
height and number of windings of the helix as well as dimensions of the relevant cross-section) based 
on the evaluation of the printed prototypes. Helices based on PVA05GLY-ALP were printed at 190 
°C requiring the use of raft and supports to avoid collapse of the incomplete item during deposition 
of successive layers. The printing speed was kept relatively low (23 mm/s) to avoid dragging of the 
latest layered material and reduce the vibrational stress undergone by the object during fabrication, 
which could cause its detachment from the build plate. The temporary shape was obtained by manual 
supercoiling of the helices, thus decreasing their diameter and reducing the distance between the 
different windings. Virtual models of the original shape were developed starting from the helix design 
already proposed for the intravesical device. Having the average dimensions of the open pyloric 
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sphincter as a reference, helices having diameter of 15 mm, height of 17 mm, number of windings of 
1.5, thickness and height of the rectangular cross-section of 3 and 0.7 mm, respectively, were finally 
selected as a result of the trial-and-error design activity. Helix-shaped samples with these 
characteristics were identified as a satisfactory balance between encumbrance of the original 
configuration and mechanical resistance to undergo manual programming of a supercoiled temporary 
shape for insertion into capsules. In this respect, size AA DB capsules were selected as their internal 
diameter (approximately 9.4 mm) allowed the supercoiled helices to be housed. In Figure 4, virtual 
model and photographs of the selected 3D printed sample in the original and temporary shapes are 
reported. 4D printed systems had average weight of 571.70 mg (cv = 7.31) and drug load of 9.82% 
(cv = 4.06). 
 
 
Figure 4: (a) virtual model with dimensional details and photographs of a cylindrical helix-shaped 
sample printed from PVA05GLY-ALP in the (b) original and (c) temporary shape. 
 
3.4 Performance of 4D printed prototypes 
Evaluation of shape recovery and release testing of the printed items in the final configuration 
intended for oral intake (i.e. helices in their temporary shape, inserted into capsules) were carried out 
in acidic fluid. Photographs of a system maintained at 37 ± 0.5 °C time under unstirred conditions are 
reported in Table 2. 
Immediately after immersion in HCl 0.1 N, the capsule began to soften. Breakup occurred on the 
capsule side and was complete in 3 min, in spite of a doubled wall thickness resulting from cap and 
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body being overlapped. A major role of the pressure exerted by the helical device starting to expand 
was evident. In fact, analogous capsules filled with a blue powder tracer, tested under the same 
conditions, were shown to open in not less than 10 min, as highlighted by solvent staining. Moreover, 
when the capsule was ruptured and a wider exposure of the sample to the acidic medium was possible, 
shape modification occurred faster. This was expected due to the combined effect of temperature and 
water on the shape memory of PVA already investigated (Melocchi A. et al., 2019). By visual 
inspection shape changes were no longer evident after 10 min, period of time during which extensive 
recovery of the original shape was achieved. 
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t = 0 t = 90 s t = 3 min t = 5 min t = 10 min 
 
Table 2: photographs acquired during shape recovery of a cylindrical helix-shaped sample printed from PVA05GLY-ALP, inserted into a DB 
capsule after programming of the temporary supercoiled shape. 
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For release testing, systems conveyed within capsules were immersed free into the vessels, regardless 
their expected tendency to float, because the presence of any constraints (e.g. sinkers) might have 
impacted on shape recovery. Floating was indeed observed though helical devices were released from 
the capsules in a few minutes while expanding and sinking. Drug release from the 4D printed systems 
was sustained over 2 h (Figure 5). 
 
Figure 5: average release profile from cylindrical helix-shaped samples printed from PVA05GLY-
ALP, inserted into DB capsules after programming of the temporary supercoiled shape. 
 
3.5 HME of prototypes 
Given the promising results obtained using FDM, which is currently proposed for customization of 
delivery systems, SMX GRDDSs having different design, mechanical characteristics, duration of 
retention and release kinetics were worth investigating (Zema et al., 2016). In this respect, a complete 
analysis of the thermo-mechanical behavior of PVA-based materials and devices through numerical 
simulations is ongoing. This approach would provide tools for the definition of the features of the 
system, reducing the number of experimental campaigns and the time as well as costs for testing. 
Starting from an empirical point of view, a simple approach was here adopted for the definition of 
further shapes of the device. The production was based on HME as this technology can overcome 
limits observed when printing by FDM high-viscosity materials (Melocchi et al., 2019). A higher 
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molecular weight PVA, i.e. PVA18, was selected for the manufacturing of new prototypes, which 
would enable a better control of drug release rate. 
The SMX GRDDS was conceived in different bulky original configurations, which could be achieved 
by post-processing of the extruded rod, i.e. by wrapping it around purposely-designed 3D printed 
templates of selected shapes. To simplify the experimental approach, all systems were obtained from 
a PVA18GLY-ALP rod of 1 mm in diameter. The method was inspired by that industrially used to 
produce corrugated breathing pipes via HME (Chan and Yi, 1989; Kolosov et al., 2012a, 2012b; 
Sidorov 2012; Sutton et al., 2010). The designed templates involved different rod lengths to yield the 
original shapes, resulting in differing amounts of drug contained in samples of diverse shape. In this 
way, dose modification may also be pursued. Virtual models of templates and of items shaped by 
their use, i.e. cylindrical and conical helix-, S- and atom-shaped samples, are reported in Figure 6, 
together with photographs of the prototypes actually obtained. The design of templates was the 
challenging step. Templates were conceived to allow easy manual wrapping of the material coming 
out of the extruder. Accordingly, the dimensions of the groove were adjusted to enable effortless 
fitting of the rods. Moreover, when possible, a stem was included in the template to serve as a handle, 
thus facilitating wrapping operations. Size attributes imposed for the system were at least 2 
dimensions > 20 mm and deformation to a temporary shape suitable for being contained in capsules 
not larger than the 00el ones (i.e. body external diameter = 8.18 mm and length of the closed capsule 
25.3 mm). These were referred to as the standard size not to be exceeded for preserved patient 
acceptance and compliance (https://www.fda.gov/downloads/drugs/guidances/ucm377938.pdf; 
https://unitaid.org/assets/Lyndra-NC-September-2018.pdf). 
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Figure 6: (a) virtual models of templates and (b) photographs of the samples obtained from 
cylindrical PVA18GLY-ALP rods of 1 mm in diameter. 
 
In Table 3, the weight and ALP content data relevant to prototypes having different original 
configurations are reported. An amount of ALP consistent with the nominal one was measured from 
samples having different weights, thus confirming that no significant loss of drug occurred during 
HME. Moreover, weight variability of samples was reduced with respect to the printed items. This 
was partly attributed to the use of templates serving as a grid for wrapping and controlling the length 
of the rod. 
 
Table 3: weight and drug content of samples having different original shapes. 
 weight 
mg (cv) 
ALP content 
% on nominal (cv) 
Cylindrical helix-shaped samples 300.07 (3.17) 98.8 (2.24) 
Conical helix-shaped samples 298.62 (4.09) 99.3 (1.93) 
S-shaped samples  140.87 (5.21) 99.1 (2.10) 
Atom-shaped samples 401.87 (4.23) 99.6 (1.89) 
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Templates to be employed for programming the temporary shape of the prototypes under 
development were also designed and 3D printed. Virtual models of the latter and photographs of 
samples deformed by their use are reported in Figure 7. With both conical and cylindrical helices, the 
same temporary shape, consisting in a supercoiled cylindrical helix, was used. On the other hand, S-
shaped and atom-shaped samples were forced to take on paper clip and elliptical shapes, respectively. 
All these temporary shapes were demonstrated to fit into the 00el capsules (Figure 7c). Also in the 
programming step, the use of templates was proved useful to enhance the reproducibility of the 
process, making it less dependent on the operator. 
 
Figure 7: (a) virtual models for templates used to program the temporary shape and (b) 
photographs of the samples deformed by their use, obtained from PVA18GLY-ALP systems having 
different original shapes; (c) photographs of the deformed samples inserted into size 00el Coni-
Snap capsules. 
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3.6 Performance of extruded prototypes 
Cylindrical and conical helix-, S- and atom-shaped samples in their original shape, along with 
cylindrical helix-shaped ones coated with Eudragit RS/ Eudragit RL 1/1, were evaluated for release 
(Figure 8). 
From all the uncoated devices, similar release patterns were obtained, pointing out negligible role of 
the length. Drug release was prolonged for approximately 2 h. The release performance was not 
improved with respect to the printed PVA05-based specimens, despite the use of a higher molecular 
weight PVA. This was ascribed to the higher surface/volume ratio of the extruded systems (about 4 
mm-1) as compared with the printed ones (3.5 mm-1). The selected die, resulting in relatively small 
size of the rod, was chosen in that it allowed a variety of temporary shapes to be easily obtained and 
compared. 
The attempt to prolong the duration of release through application of an insoluble/permeable coating, 
such as resulting from the commonly used Eudragit RS/ Eudragit RL mixture, was proven 
effective, thus highlighting a possible formulation strategy worthy of further investigation. 
 
Figure 8: average release profiles from coated and uncoated extruded PVA18GLY-ALP samples 
having different original shapes. 
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Further tests were performed with uncoated samples inserted into capsules. All the prototypes showed 
ability to recover the original shape except for the atom-shaped ones. This might be associated with 
the temporary shape imposed, characterized by many tight folds and thus involving longer lasting 
manual processing at the deformation temperature. As for the 4D printed prototypes, also the extruded 
systems showed the most marked changes in terms of shape recovery within the first minutes of 
testing. By way of example, photographs of a system having original conical helical shape, 
maintained at 37 ± 0.5 °C under unstirred conditions, are reported in Table 4. Breakup of the capsule 
occurred after 45 s. Also with extruded samples, the effect of the force exerted by the inner prototype 
while recovering its shape was evident. RI relevant to samples having conical and cylindrical helical 
shapes as well as S shape was also measured (Figure 9 and 10). In order to monitor increase in spatial 
encumbrance of the systems over time, specific RIs were calculated for each shape. In all cases, 
exceeding dimensions of 13 mm was used as the criterion for acceptable shape recovery. 
When dealing with conical and cylindrical helices, recovery of the initial diameter was considered 
the crucial step. In fact, the length of such items in the supercoiled temporary shape was already > 20 
mm. A diameter greater than or equal to 13 mm, corresponding to a RIØ of 41% and 23% for 
cylindrical and conical helices, respectively, was achieved in less than 2 min (Figure 9a and 9b). 
Moreover, the samples gained approximately 90% and 60% of their original diameter within 5 min 
of testing. The time for reaching the threshold dimension was relatively short, which could be 
attributed to the combined effect of temperature and fast water uptake of the systems. This was 
considered potentially suitable for addressing a major safety issue of expandable GRDDSs, connected 
with the time needed to achieve the bulky retentive configuration. Indeed, late expansion might result 
in small intestine location of the system with possible clogging of the canal, and also loss of the 
absorption window with consequent reduction of bioavailability. 
To define the overall spatial encumbrance of the helices, RIØ/h was also evaluated. Setting the 
diameter-to-height ratio of samples in their original shape equal to 100, cylindrical helices exhibited 
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the ability to reach 77% of RIØ/h in 5 min, while items with conical helical shape recovered about 
60% in the same time frame. 
Because recovery of S shape involved the opening of the temporary paper-clip configuration, it was 
evaluated by measuring three angles associated with xy, zx and yz planes, i.e. αxy, αxz, and αyz (Figure 
2c and Figure 10). For these systems, simultaneous widening of two angles would be sufficient to 
achieve size compatible with gastric retention. 43°, 33° and 32° were calculated to be the threshold 
limits for αxy, αxz, and αyz, respectively. Such values were always reached within 5 min of testing and 
kept increasing. Evident changes were no longer recorded after 15 min. In this time frame, αxy and 
αyz achieved approximately 70% of recovery, while αxz reached almost 90%. This could be associated 
with the possibility of the system to freely move in the xz plane, while the opening of αxy and αyz 
might have been hindered by the sliding friction on the bottom surface of the crystallization vessel. 
Evaluation of the shape memory performance was also carried out after storage of the prototype-
containing capsules at ambient conditions for at least 1 month and no major changes were highlighted. 
Release profiles of prototypes in their temporary shape, tested either free or inserted into capsules, 
were shown to be analogous to that of samples in their original shape, confirming the robustness of 
the SMX GRDDS under development. 
As regards cylindrical helix-shaped samples provided with the Eudragit® RS/ Eudragit® RL coating, 
promising results were preliminary obtained demonstrating their capability of being programmed in 
the temporary supercoiled configuration, recovering the original shape upon contact with aqueous 
fluid at body temperature and slowly releasing the drug tracer over 6 h. 
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t = 0 t = 45 s t = 1 min and 30 s t = 3 min t = 5 min 
 
Table 4: photographs acquired during shape recovery of a conical helix-shaped sample extruded from PVA05GLY-ALP, inserted into size 00el 
Coni-Snap capsule after programming of the temporary supercoiled shape. 
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Figure 9: RIØ versus time curves relevant to samples having original (a) cylindrical and (b) conical 
helical shapes. The dashed lines represent threshold RIØ. 
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Figure 10: RIα(x,y,z) versus time curves relevant to samples having original S shape. The dashed 
lines represent threshold RIα(x,y,z). 
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4. Conclusions 
In the present work, a novel expandable GRDDS was described. Gastric retention is of great interest 
in the case of drugs that are absorbed to a greater extent in the upper gastrointestinal tract or indicated 
for the therapy of widespread local diseases. Indeed, they would increase patient compliance because 
of reduced frequency of administration and enhance the therapy efficacy. The strategy here pursued 
was based on the use of pharmaceutical-grade PVA, which was already proved to be endowed with 
shape memory ability. This would allow the system to spontaneously shift from a temporary shape 
programmed by deformation, suitable for oral administration, to an expanded original one enabling 
gastric retention due to proper spatial encumbrance. The proposed device could thus be considered a 
shape-memory expandable GRDDS (SMX GRDDS). Because the relevant expansion mechanism is 
based on the combination of body temperature and contact with a minimum volume of fluids, the 
system may only poorly be susceptible to physiological variables of the gastric environment. 
Prototypes having different original shapes were successfully manufactured either directly by 4D 
printing or by manual processing of extruded rods. A quantitative method was set up to evaluate shape 
modifications undergone by extruded samples over time in unstirred acidic environment at 37 ± 0.5 
°C. The temporary shape enabled, in all cases, insertion into commercial gelatin capsules of widely 
used sizes. A satisfactory extent of recovery of the original cylindrical and conical helix as well as S 
shapes was reached in a few minutes with respect to a previously set threshold value. Shape changes 
imposed through heating and mechanical deformation were demonstrated not to impact on the release 
performance of prototypes. However, the timescale of the release process was found to be an issue, 
in view of the longer-lasting performance that is known to be required for GRDDSs. In this respect, 
the application of a diffusive polymeric film onto cylindrical extruded helices was demonstrated a 
suitable formulation approach to prolong release over 6 h. 
In future development studies, further improvement of the duration of release could be pursued 
primarily entailing selection of different release-controlling coating formulations, of PVAs with 
higher molecular weights or else of different shape memory polymers. Moreover, modification in the 
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overall surface/volume ratio of the device and changes in the length of extruded rods to increase the 
drug load will be taken into account. In this respect, the versatility that the manufacturing approach 
would provide could be advantageous. An in-depth evaluation of the mechanical behavior of the 
system and the contribution of temperature and amount of water on its expansion will also be 
performed. 
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